<!DOCTYPE html>
<html lang="zh-CN">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=5.0">
    <title>ç§‘ç ”æ—¥æŠ¥ - 2025-12-20</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", Arial, "Noto Sans", sans-serif, "Apple Color Emoji", "Segoe UI Emoji";
            line-height: 1.8;
            color: #2c3e50;
            background: linear-gradient(135deg, #f5f7fa 0%, #c3cfe2 100%);
            padding: 15px;
            font-size: 16px;
        }

        .container {
            max-width: 900px;
            margin: 0 auto;
            background: white;
            padding: 35px;
            border-radius: 16px;
            box-shadow: 0 10px 40px rgba(0,0,0,0.1);
        }

        /* æ ‡é¢˜ä¼˜åŒ– */
        h1 {
            color: #1a202c;
            font-size: 2em;
            border-bottom: 4px solid #667eea;
            padding-bottom: 15px;
            margin-bottom: 25px;
            font-weight: 700;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
        }

        h2 {
            color: #2d3748;
            font-size: 1.5em;
            margin-top: 40px;
            margin-bottom: 20px;
            padding-left: 15px;
            border-left: 5px solid #667eea;
            font-weight: 600;
        }

        h3 {
            color: #4a5568;
            font-size: 1.25em;
            margin-top: 28px;
            margin-bottom: 14px;
            font-weight: 600;
        }

        /* åˆ†ç±»æµè§ˆæŠ˜å åŠŸèƒ½ */
        details {
            margin: 20px 0;
            border-radius: 8px;
            overflow: hidden;
        }

        details summary {
            cursor: pointer;
            padding: 15px 20px;
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            color: #2d3748;
            font-size: 1.25em;
            font-weight: 600;
            text-align: right;
            direction: rtl;
            border-right: 5px solid #667eea;
            transition: all 0.3s ease;
            list-style: none;
            user-select: none;
        }

        details summary * {
            direction: ltr;
        }

        details summary::-webkit-details-marker {
            display: none;
        }

        details summary::before {
            content: 'â–¶';
            display: inline-block;
            margin-left: 10px;
            transition: transform 0.3s ease;
            font-size: 0.8em;
        }

        details[open] summary::before {
            transform: rotate(90deg);
        }

        details summary:hover {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            box-shadow: 0 4px 12px rgba(102, 126, 234, 0.3);
        }

        details[open] summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            border-right-color: white;
        }

        details .details-content {
            padding: 20px;
            background: white;
            border: 1px solid #e9ecef;
            border-top: none;
        }

        h4 {
            color: #718096;
            font-size: 1.1em;
            margin-top: 22px;
            margin-bottom: 12px;
            font-weight: 600;
        }

        p {
            margin-bottom: 16px;
            line-height: 1.8;
        }

        blockquote {
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            border-left: 4px solid #667eea;
            padding: 18px 22px;
            margin: 22px 0;
            border-radius: 8px;
            color: #4a5568;
            font-size: 0.95em;
            box-shadow: 0 2px 8px rgba(0,0,0,0.05);
        }

        blockquote p {
            margin-bottom: 8px;
        }

        blockquote p:last-child {
            margin-bottom: 0;
        }

        blockquote em {
            font-style: normal;
            color: #718096;
            font-size: 0.9em;
        }

        blockquote a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        blockquote a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* é¡¶éƒ¨ç½²åï¼ˆå±…å³ï¼‰ */
        .powered-by-top {
            text-align: right;
            font-size: 0.85em;
            color: #718096;
            font-style: italic;
            margin: 12px 0;
            padding-right: 5px;
        }

        .powered-by-top a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        .powered-by-top a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* AI æ€»ç»“åŒºåŸŸä¼˜åŒ– */
        .ai-summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            padding: 28px;
            border-radius: 16px;
            margin: 30px 0;
            box-shadow: 0 12px 35px rgba(102, 126, 234, 0.35);
            position: relative;
            overflow: hidden;
        }

        .ai-summary::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -50%;
            width: 200%;
            height: 200%;
            background: radial-gradient(circle, rgba(255,255,255,0.1) 0%, transparent 70%);
            pointer-events: none;
        }

        .ai-summary h2 {
            color: white;
            border-left: none;
            border-right: none;
            margin-top: 0;
            margin-bottom: 18px;
            padding-left: 15px;
            padding-right: 0;
            text-align: left;
            direction: ltr;
        }

        .ai-summary h3 {
            color: #f0f0f0;
            margin-top: 18px;
            border-right: 3px solid rgba(255,255,255,0.5);
            padding-right: 12px;
            padding-left: 0;
            text-align: right;
            direction: rtl;
        }

        .ai-summary h3 * {
            direction: ltr;
        }

        .ai-summary blockquote {
            background: rgba(255,255,255,0.15);
            border-left-color: white;
            color: white;
            backdrop-filter: blur(10px);
        }

        .ai-summary p {
            color: white;
        }

        .ai-summary strong {
            color: #fff;
            font-weight: 600;
        }

        ul, ol {
            margin-left: 28px;
            margin-bottom: 18px;
        }

        li {
            margin-bottom: 12px;
            line-height: 1.8;
        }

        /* é“¾æ¥ä¼˜åŒ– */
        a {
            color: #667eea;
            text-decoration: none;
            border-bottom: 1px solid transparent;
            transition: all 0.3s ease;
            font-weight: 500;
        }

        a:hover {
            border-bottom-color: #667eea;
            color: #764ba2;
        }

        /* è¡¨æ ¼ä¼˜åŒ– */
        table {
            width: 100%;
            border-collapse: collapse;
            margin: 20px 0;
            box-shadow: 0 2px 12px rgba(0,0,0,0.08);
            border-radius: 10px;
            overflow: hidden;
        }

        th, td {
            border: 1px solid #e2e8f0;
            padding: 14px 18px;
            text-align: left;
        }

        th {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            font-weight: 600;
            font-size: 0.95em;
        }

        tr:nth-child(even) {
            background: #f8f9fa;
        }

        tr:hover {
            background: #e9ecef;
            transition: background 0.3s ease;
        }

        /* å…³é”®è¯ç»Ÿè®¡è¡¨æ ¼ç‰¹æ®Šæ ·å¼ï¼ˆæ›´ç´§å‡‘ï¼‰ */
        .keywords-table {
            font-size: 0.9em;
            max-width: 600px;
        }

        .keywords-table th,
        .keywords-table td {
            padding: 10px 14px;
        }

        .keywords-table th {
            font-size: 0.9em;
        }

        hr {
            border: none;
            border-top: 2px solid #e2e8f0;
            margin: 40px 0;
        }

        strong {
            color: #2d3748;
            font-weight: 600;
        }

        code {
            background: #f1f5f9;
            padding: 3px 8px;
            border-radius: 5px;
            font-family: "SF Mono", Monaco, Consolas, "Courier New", monospace;
            font-size: 0.9em;
            color: #e53e3e;
        }

        /* ç¾åŒ–æ»šåŠ¨æ¡ */
        ::-webkit-scrollbar {
            width: 8px;
            height: 8px;
        }

        ::-webkit-scrollbar-track {
            background: #f1f1f1;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb {
            background: #667eea;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb:hover {
            background: #764ba2;
        }

        /* ç§»åŠ¨ç«¯ä¼˜åŒ– */
        @media (max-width: 768px) {
            body {
                padding: 8px;
                font-size: 15px;
            }

            .container {
                padding: 22px 18px;
                border-radius: 12px;
            }

            h1 {
                font-size: 1.6em;
                padding-bottom: 12px;
                margin-bottom: 20px;
            }

            h2 {
                font-size: 1.3em;
                margin-top: 30px;
                padding-left: 12px;
            }

            h3 {
                font-size: 1.15em;
            }

            h4 {
                font-size: 1.05em;
            }

            blockquote {
                padding: 14px 16px;
                margin: 18px 0;
            }

            .ai-summary {
                padding: 20px;
                margin: 22px 0;
            }

            .ai-summary-header {
                flex-direction: column;
                align-items: flex-start;
            }

            .powered-by {
                margin-left: 0;
                margin-top: 8px;
            }

            table {
                font-size: 0.85em;
            }

            th, td {
                padding: 10px 12px;
            }

            .keywords-table {
                font-size: 0.8em;
            }

            .keywords-table th,
            .keywords-table td {
                padding: 8px 10px;
            }

            ul, ol {
                margin-left: 22px;
            }
        }

        /* è¶…å°å±å¹• */
        @media (max-width: 480px) {
            body {
                font-size: 14px;
                padding: 5px;
            }

            .container {
                padding: 18px 14px;
            }

            h1 {
                font-size: 1.4em;
            }

            h2 {
                font-size: 1.2em;
            }

            .ai-summary {
                padding: 16px;
            }

            .powered-by {
                font-size: 0.7em;
            }
        }

        /* å¹³æ»‘æ»šåŠ¨ */
        html {
            scroll-behavior: smooth;
        }

        /* æé«˜å¯ç‚¹å‡»åŒºåŸŸ */
        @media (pointer: coarse) {
            a {
                padding: 4px 0;
                display: inline-block;
            }
        }

        /* æ‰“å°ä¼˜åŒ– */
        @media print {
            body {
                background: white;
                padding: 0;
            }

            .container {
                box-shadow: none;
                max-width: 100%;
            }

            .ai-summary {
                background: #f5f5f5;
                color: black;
                box-shadow: none;
            }

            .ai-summary h2,
            .ai-summary h3,
            .ai-summary p,
            .ai-summary strong {
                color: black;
            }
        }
    </style>
</head>
<body>
    <div class="container">
        <h1>ğŸ“… Daily Report - 2025-12-20</h1>
<blockquote>
<p>ä»Šæ—¥ç­›é€‰å‡º <strong>41</strong> æ¡å†…å®¹ï¼Œæ¥è‡ª <strong>2</strong> ä¸ªæ¥æº</p>
</blockquote>
<div class="powered-by-top">Powered by <a href="https://kyplus.de" target="_blank" rel="noopener noreferrer">ç§‘ç ”æ™®æ‹‰æ–¯</a> & <a href="https://claude.ai" target="_blank" rel="noopener noreferrer">Claude</a></div>

<hr />
<div class="ai-summary">
                <h2>ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“</h2>
                <h3>ğŸ§¬ æ•°æ®å‰æ²¿</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
DeCAFæŠ€æœ¯çªç ´æ€§åœ°æ­ç¤ºäº†èƒ°è…ºç™Œä¸­ç™Œç›¸å…³æˆçº¤ç»´ç»†èƒï¼ˆCAFï¼‰çš„å¤šç»´åº¦å¼‚è´¨æ€§ï¼Œå¹¶é˜æ˜å…¶åœ¨è‚¿ç˜¤è¿›å±•å’Œå…ç–«æ²»ç–—å“åº”ä¸­çš„ä½œç”¨ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- <strong>è‚¿ç˜¤å¾®ç¯å¢ƒä¸å…ç–«æ²»ç–—</strong>ï¼šç ”ç©¶ç™Œç›¸å…³æˆçº¤ç»´ç»†èƒï¼ˆCAFï¼‰å¼‚è´¨æ€§å¯¹èƒ°è…ºç™Œè¿›å±•åŠå…ç–«æ²»ç–—å“åº”çš„å½±å“ï¼›æ¢ç´¢è„‚è´¨é©±åŠ¨çš„å…ç–«ä»£è°¢é€šè·¯åœ¨åµå·¢ç™Œè…¹è†œè½¬ç§»ä¸­å¢å¼ºå…ç–«æ²»ç–—çš„æ½œåŠ›ï¼›è§£æESR1çªå˜å¯¹ä¹³è…ºè‚¿ç˜¤å…ç–«æŠ‘åˆ¶å¾®ç¯å¢ƒçš„è´¡çŒ®ã€‚<br />
- <strong>è¡°è€ä¸è¡¨è§‚é—ä¼ </strong>ï¼šåˆ©ç”¨å•æ ¸ç”²åŸºåŒ–æµ‹åºæ­ç¤ºå¤§è„‘è¡°è€çš„è¡¨è§‚é—ä¼ ç‰¹å¾ã€‚<br />
- <strong>åŸºå› ç»„ç¨³å®šæ€§ä¸ç»†èƒå‘¨æœŸ</strong>ï¼šé˜æ˜Poloæ ·æ¿€é…¶Cdc5å’Œç£·é…¸é…¶Cdc14åœ¨æœ‰ä¸åˆ†è£‚ä¸­è°ƒæ§æ‹“æ‰‘å¼‚æ„é…¶IIä»‹å¯¼çš„å§å¦¹æŸ“è‰²å•ä½“è”ä¼šè§£èšçš„å…³é”®æœºåˆ¶ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- <strong>ç©ºé—´è½¬å½•ç»„å­¦</strong>ï¼šé¦–æ¬¡ç”¨äºè§£æè‚¿ç˜¤å¾®ç¯å¢ƒä¸­çš„ç»†èƒå¼‚è´¨æ€§ã€‚<br />
- <strong>å¤šç»„å­¦æ•´åˆ</strong>ï¼šç»“åˆATAC-Seqä¸åŸºå› è¡¨è¾¾æµ‹åºï¼Œæ·±å…¥ç ”ç©¶èƒšèƒå‘è‚²è¿‡ç¨‹ä¸­çš„æŸ“è‰²è´¨è°ƒæ§ã€‚</p>
<h3>ğŸ§ª åšå®¢æ›´æ–°</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
ç§‘å­¦å®¶é¦–æ¬¡å‘ç°Tç»†èƒå—ä½“æ¿€æ´»å­˜åœ¨éšè—çš„å¼¹ç°§å¼è¿åŠ¨ï¼Œæœ‰æœ›æå‡ç™Œç—‡å…ç–«ç–—æ³•çš„æœ‰æ•ˆæ€§ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- SARS-CoV-2æ„ŸæŸ“å½±å“è‚ºç»†èƒé•¿é“¾éç¼–ç RNAï¼ˆlncRNAsï¼‰çš„m6Aç”²åŸºåŒ–ï¼Œé‡å¡‘æŠ—ç—…æ¯’ååº”ã€‚<br />
- æ¶²ä½“æ´»æ£€ä¸­RNAç”²åŸºåŒ–æ ‡å¿—ç‰©å¯ä½œä¸ºè‚ºç™Œè¯Šæ–­çš„äº’è¡¥ç”Ÿç‰©æ ‡å¿—ç‰©ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- çº³ç±³å­”æŠ€æœ¯RNAæµ‹åºæ­ç¤ºè¡€æ¶²ä¸­å°RNAçš„ç”²åŸºåŒ–ç‰¹å¾ã€‚</p>
            </div><h2>ğŸ“š åˆ†ç±»æµè§ˆ</h2>
<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§¬ æ•°æ®å‰æ²¿ (38æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰</h4>
<p><strong>1.</strong> â­ <strong>GSE311783 DeCAF é‡æ–°å®šä¹‰äº†æˆçº¤ç»´ç»†èƒçŠ¶æ€ï¼Œæ­ç¤ºäº†é©±åŠ¨ä¸´åºŠè‚¿ç˜¤è¿›å±•å’Œå…ç–«æ²»ç–—ååº”çš„å¤šç»´è‚¿ç˜¤-åŸºè´¨å…³ç³» [ç©ºé—´è½¬å½•ç»„å­¦]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€regex:immuno(logy|therapy|suppression)ã€spatialã€spatial transcriptomicsã€transcriptomics<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Xianlu L Peng ; Ian C McCabe ; Jen Jen YehSeries Type : OtherOrganism : Homo sapiensCancer-associated fibroblast (CAF) heterogeneity within pancreatic ductal adenocarcinoma (PDAC) has been previously assessed through single-cell RNA sequencing (scRNAseq) to discover distinct CAF populations such as myCAFs and iCAFs. While useful as a biological framework, no studies have conclusively and robustly demonstrated a correlation of CAF subpopulations with clinical prognosis or therapy response. We define restraining (rest) and promoting (pro) CAFs in patient samples that are both prognostic and predictive of therapy response in disparate tumor types. Using a single sample classifier, DeCAF, we uncover distinct clinical and spatial interactions between pro- and restCAF subtypes and basal-like and classical tumor subtypes that support tumor stroma crosstalk where basal-like tumors are enriched in proCAFs and classical tumors are enriched in restCAFs. Finally, we find striking differences in the immune contexture of pro- and restCAF tumors where restCAF dominant tumors are enriched in patients who respond to immune checkpoint inhibition (ICI) in two large clinical trials, and proCAF dominant tumors are enriched in patients who respond to myeloid inhibition. This work is the first to define CAF subtypes that are clinically robust, prognostic, predictive of immunotherapy response, and associate with tumor molecular subtype.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311783" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> â­ <strong>GSE169236 é€šè¿‡å•æ ¸ç”²åŸºåŒ–æµ‹åºç ”ç©¶å¤§è„‘è¡°è€çš„è¡¨è§‚é—ä¼ ç‰¹å¾ [CP-9mo-m-023]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šagingã€sequencingã€epigeneticã€methylation<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Wei Tian ; Anna Bartlett ; Jordan Altshul ; Rosa Gomez Castanon ; Joseph R Nery ; Jacinta D Lucero ; Julia K Osteen ; Huaming Chen ; M M Behrens ; Joseph R EckerSeries Type : Methylation profiling by high throughput sequencingOrganism : Mus musculusIllustrating aging effects on the epigenomic features of brain is critical to understand brain functional decline and neurodegeneration. Single nucleus methylation sequencing was applied to brain regions of both male and female mouse at the age of 2, 9 and 18 months. We use these data to identify the epigenomic changes with aging in mouse brains.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE169236" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> â­ <strong>GSE169251 é€šè¿‡å•æ ¸ç”²åŸºåŒ–æµ‹åºç ”ç©¶å¤§è„‘è¡°è€çš„è¡¨è§‚é—ä¼ ç‰¹å¾ [DHC-9mo-m-001]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šagingã€sequencingã€epigeneticã€methylation<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Wei Tian ; Anna Bartlett ; Jordan Altshul ; Rosa Gomez Castanon ; Joseph R Nery ; Jacinta D Lucero ; Julia K Osteen ; Huaming Chen ; M M Behrens ; Joseph R EckerSeries Type : Methylation profiling by high throughput sequencingOrganism : Mus musculusIllustrating aging effects on the epigenomic features of brain is critical to understand brain functional decline and neurodegeneration. Single nucleus methylation sequencing was applied to brain regions of mouse at the age of 2, 9 and 18 months. We use these data to identify the epigenomic changes with aging in mouse brains.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE169251" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> â­ <strong>GSE311788 DeCAF é‡æ–°å®šä¹‰äº†æˆçº¤ç»´ç»†èƒçŠ¶æ€ï¼Œæ­ç¤ºäº†é©±åŠ¨ä¸´åºŠè‚¿ç˜¤è¿›å±•å’Œå…ç–«æ²»ç–—ååº”çš„å¤šç»´è‚¿ç˜¤-åŸºè´¨å…³ç³» [scRNA-Seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€regex:immuno(logy|therapy|suppression)ã€scRNA<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Xianlu L Peng ; Ian C McCabe ; Jen Jen YehSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensCancer-associated fibroblast (CAF) heterogeneity within pancreatic ductal adenocarcinoma (PDAC) has been previously assessed through single-cell RNA sequencing (scRNAseq) to discover distinct CAF populations such as myCAFs and iCAFs. While useful as a biological framework, no studies have conclusively and robustly demonstrated a correlation of CAF subpopulations with clinical prognosis or therapy response. We define restraining (rest) and promoting (pro) CAFs in patient samples that are both prognostic and predictive of therapy response in disparate tumor types. Using a single sample classifier, DeCAF, we uncover distinct clinical and spatial interactions between pro- and restCAF subtypes and basal-like and classical tumor subtypes that support tumor stroma crosstalk where basal-like tumors are enriched in proCAFs and classical tumors are enriched in restCAFs. Finally, we find striking differences in the immune contexture of pro- and restCAF tumors where restCAF dominant tumors are enriched in patients who respond to immune checkpoint inhibition (ICI) in two large clinical trials, and proCAF dominant tumors are enriched in patients who respond to myeloid inhibition. This work is the first to define CAF subtypes that are clinically robust, prognostic, predictive of immunotherapy response, and associate with tumor molecular subtype.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311788" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>5.</strong> â­ <strong>GSE310957 DeCAF é‡æ–°å®šä¹‰äº†æˆçº¤ç»´ç»†èƒçŠ¶æ€ï¼Œæ­ç¤ºäº†é©±åŠ¨ä¸´åºŠè‚¿ç˜¤è¿›å±•å’Œå…ç–«æ²»ç–—ååº”çš„å¤šç»´è‚¿ç˜¤-åŸºè´¨å…³ç³» [RNA-Seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€regex:immuno(logy|therapy|suppression)ã€RNA-seq<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Xianlu L Peng ; Ian C McCabe ; Jen Jen YehSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensCancer-associated fibroblast (CAF) heterogeneity within pancreatic ductal adenocarcinoma (PDAC) has been previously assessed through single-cell RNA sequencing (scRNAseq) to discover distinct CAF populations such as myCAFs and iCAFs. While useful as a biological framework, no studies have conclusively and robustly demonstrated a correlation of CAF subpopulations with clinical prognosis or therapy response. We define restraining (rest) and promoting (pro) CAFs in patient samples that are both prognostic and predictive of therapy response in disparate tumor types. Using a single sample classifier, DeCAF, we uncover distinct clinical and spatial interactions between pro- and restCAF subtypes and basal-like and classical tumor subtypes that support tumor stroma crosstalk where basal-like tumors are enriched in proCAFs and classical tumors are enriched in restCAFs. Finally, we find striking differences in the immune contexture of pro- and restCAF tumors where restCAF dominant tumors are enriched in patients who respond to immune checkpoint inhibition (ICI) in two large clinical trials, and proCAF dominant tumors are enriched in patients who respond to myeloid inhibition. This work is the first to define CAF subtypes that are clinically robust, prognostic, predictive of immunotherapy response, and associate with tumor molecular subtype.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310957" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>6.</strong> â­ <strong>GSE313840 å•ç»†èƒæµ‹åºæ­ç¤ºæŸ¯è¨å¥‡ç—…æ¯’ A6 ç›¸å…³æ‰‹è¶³å£ç—…åœ¨å„¿ç«¥ä¸­çš„å…ç–«ç‰¹å¾</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šimmuneã€sequencingã€single-cell<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Meng Zhang ; Huiling Deng ; Chenrui Liu ; Na Huang ; Ling He ; Yaping LiSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensHand, foot, and mouth disease (HFMD) is a clinically significant pediatric infection with potential neurological complications, and coxsackievirus A6 (CA6) is increasingly recognized as a predominant causative agent. We identified significant alterations in immune cell composition and amino acid metabolism during disease progression through an integrated multiomics analysis of pediatric patients with CA6-associated HFMD. Single-cell RNA sequencing revealed dynamic changes in peripheral blood mononuclear cell populations, particularly in CD4+ naÃ¯ve T cells, neutrophils, and CD16- monocytes.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313840" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>7.</strong> â­ <strong>GSE310918 åˆ©ç”¨è„‚è´¨é©±åŠ¨çš„å…ç–«ä»£è°¢é€šè·¯å¢å¼ºå¤§ç½‘è†œè½¬ç§»ç˜¤çš„å…ç–«æ²»ç–—æ•ˆæœ</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€metabolicã€regex:immuno(logy|therapy|suppression)<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Meggy Suarez-Carmona ; Mareike Hampel ; Xin-Wen Zhang ; Alexandra PÃ¶chmann ; Silke A Grauling-Halama ; Nektarios A Valous ; Pornpimol Charoentong ; Dyke Ferber ; Jannis Wissfeld ; Alicia HÃ¶flich ; Stanislas Goriely ; AurÃ©lie Detavernier ; Abdulkader Azouz ; Anthony Rongvaux ; Sven Zukunft ; Ingrid Fleming ; JÃ¼rgen G Okun ; Vickie Baracos ; Mathias HeikenwÃ¤lder ; Laurence Zitvogel ; Xinyi Xu ; Chenqi Xu ; Michael Volkmar ; Daniel Schraivogel ; Lars Steinmetz ; Junzo Hamanishi ; Masaki Mandai ; Mathias Gaida ; Theresa Mokry ; Johanna NattenmÃ¼ller ; Oliver Sedlaczek ; Nanna MonjÃ© ; Roxanna Schwab ; Annette Hasenburg ; Regina Johanna Boger ; Frederik MarmÃ© ; Athanasios Mavratzas ; Sarah Schott ; Niels HalamaSeries Type : Expression profiling by high throughput sequencing ; OtherOrganism : Mus musculusDespite the potential of immune checkpoint blockade (ICB) in epithelial ovarian carcinoma (EOC), its clinical efficacy remains limited. Our study investigates the immuno-metabolic landscape of omental metastases to identify therapeutic targets. Using patient-derived explants (PDEs), we demonstrate that lipid-rich omental environments preserve effector T cell function, while lipid processing in tumor-associated macrophages (TAMs) induces oxidative stress and immune suppression. Targeting lipid metabolism via CCR5 inhibition (e.g., maraviroc) or anti-CD36 treatment reprograms TAMs, restores T cell activity, and enhances anti-tumor immunity. These findings reveal a metabolic-inflammatory axis that can be modulated to improve ICB outcomes in EOC.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310918" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>8.</strong> <strong>GSE311789 DeCAFé‡æ–°å®šä¹‰äº†æˆçº¤ç»´ç»†èƒçŠ¶æ€ï¼Œæ­ç¤ºäº†é©±åŠ¨ä¸´åºŠè‚¿ç˜¤è¿›å±•å’Œå…ç–«æ²»ç–—ååº”çš„å¤šç»´è‚¿ç˜¤-åŸºè´¨å…³ç³»ã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€regex:immuno(logy|therapy|suppression)<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSeries Type : Other ; Expression profiling by high throughput sequencingOrganism : Homo sapiensThis SuperSeries is composed of the SubSeries listed below.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311789" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>9.</strong> <strong>GSE288652 ç»“è‚ ä½çº§åˆ«å’Œé«˜çº§åˆ«è…ºç˜¤çš„å…¨åŸºå› ç»„DNAç”²åŸºåŒ–</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šgenomeã€methylation<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Alexis Overs ; Jean-Paul Feugeas ; Zohair Selmani ; Paul Peixoto ; Eric Hervouet ; ChloÃ© Molimard ; Laurent Arnould ; FrÃ©dÃ©ric Bibeau ; Jules DurandSeries Type : Methylation profiling by arrayOrganism : Homo sapiensIntroduction: The dynamics of colorectal epigenetics during early carcinogenesis remain undocumented. In this study, we explore the DNA methylation dynamics in colorectal cancer oncogenesis from non-tumor colon tissues to low-grade, high-grade adenoma and adenocarcinoma. Methods: The methylome of 13 low-grade and 19 high-grade colorectal adenomas was determined using the EPIC v1 Human Methylation Beadchip. These methylation profiles were complemented with the methylomes of 206 non-tumor colon and 24 colon adenocarcinomas from GSE149282, GSE132804 series and the HCMI study. Differentially methylated CpG were identified by Student's t-test and used to monitor the evolution of the colon methylome during carcinogenesis. The differentially methylated promoters were used to infer the associated biological process using gene ontology. Results: 4.9% of the colon methylome is significantly altered (p &lt; 10-4) during carcinogenesis with two thirds corresponding to DNA demethylation. 56.6% of the methylation changes occurs at the transition from non-tumor colon tissues to low-grades adenomas. 18.2% of the DNA methylation changes are transitory during low-grade and/or high-grade adenomas. The biological pathways sensory perception of odor and stimulus were early unmethylated, nervous system development and homophilic cell adhesion were early methylated, and chemical synaptic transmission and cell adhesion were transiently methylated. Conclusion: This study provides insight into the dynamics of colonic epigenetics during carcinogenesis, with early DNA methylation changes in the low-grade adenomas associated with transient DNA methylation changes. However, the causality of these changes remains to be elucidated.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE288652" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>10.</strong> <strong>GSE311611 åŒæ—¶é¶å‘ KRAS å’Œ CDK4 å¯ååŒè¯±å¯¼èƒ°è…ºç™Œç»†èƒæŒä¹…ç”Ÿé•¿åœæ»</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€KRAS<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusMutant Ras oncoproteins, particularly KRAS, are among the most prevalent drivers of cancer. Small-molecule KRAS inhibitors have emerged as promising cancer therapeutics, yet resistance development remains a major hurdle. To overcome this challenge, we explored rational combination strategies aimed at enhancing therapeutic efficacy and durability. We show that the KRAS-G12C inhibitor Sotorasib synergizes with the CDK4/6 inhibitor Palbociclib to eliminate pancreatic ductal adenocarcinoma (PDAC) cells and organoids harboring KRAS-G12C mutations. This synergy was especially pronounced following drug washout, indicating a durable cellular response. Similar synergistic effects were observed in non-small-cell lung cancer (NSCLC) cells. Additionally, the KRAS-G12D inhibitor MRTX1133 cooperated with Palbociclib to suppress KRAS-G12D-mutant PDAC cells. Mechanistically, the combinations induced sustained cell cycle arrest, marked by reduced RB phosphorylation, decreased E2F1 expression, and increased levels of CDKN1B/p27. Deletion of CDKN1B largely reversed the growth-inhibitory effect, highlighting its essential role in mediating the observed synergy. In an orthotopic, immunocompetent mouse model of PDAC, MRTX1133 significantly delayed tumor growth and extended survival; however, despite its ability to suppress RB phosphorylation, Palbociclib failed to enhance these effects. This might be due to increased tumor vascularization upon Palbociclib treatment, as revealed by single cell RNA sequencing. In summary, our findings demonstrate the therapeutic potential of enhancing cell cycle restriction point activation in KRAS inhibitor-based therapies, while emphasizing the importance of precisely adjusting the drug combinations to the in vivo situation.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311611" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<blockquote>
<p>ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 28 æ¡å†…å®¹ï¼Œè¯¦è§ <a href="#æ›´å¤š-æ•°æ®å‰æ²¿">æ–‡æœ«</a></p>
</blockquote>
</div>
</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§ª åšå®¢æ›´æ–° (3æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨3æ¡ï¼‰</h4>
<p><strong>1.</strong> â­ <strong>ä¸€ç§éšè—çš„Tç»†èƒå¼€å…³å¯èƒ½ä½¿ç™Œç—‡å…ç–«ç–—æ³•å¯¹æ›´å¤šäººæœ‰æ•ˆã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€T cellã€regex:immuno(logy|therapy|suppression)<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šScientists have discovered that T cell receptors activate through a hidden spring-like motion that had never been seen before. This breakthrough may help explain why immunotherapy works for some cancers and how it could be improved for others.<br />
- ğŸ”— <a href="https://www.sciencedaily.com/releases/2025/12/251218074429.htm" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> <strong>SARS-CoV-2æ„ŸæŸ“æ”¹å˜è‚ºç»†èƒlncRNAçš„RNAç”²åŸºåŒ–</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šmethylation<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šAltered m6A methylation detected by RNA sequencing in lung cell lncRNAs, including UCA1, GAS5 and NORAD, may reshape antiviral responses during SARS-CoV-2 infection...<br />
- ğŸ”— <a href="https://www.rna-seqblog.com/sars-cov-2-infection-alters-rna-methylation-in-lung-cell-lncrnas/" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> <strong>Hummingbird Diagnosticså…¬å¸å‘è¡¨äº†å…³äºæ¶²ä½“æ´»æ£€ä¸­RNAç”Ÿç‰©æ ‡å¿—ç‰©ç”²åŸºåŒ–çš„ç ”ç©¶æŠ¥å‘Š</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šmethylation<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šRNA sequencing using nanopore technology reveals small RNA methylation signatures in blood, highlighting RNA modifications as a complementary biomarker layer for more sensitive lung cancer liquid biopsies...<br />
- ğŸ”— <a href="https://www.rna-seqblog.com/hummingbird-diagnostics-publishes-study-on-rna-biomarker-methylation-in-liquid-biopsies/" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
</div>
</details>

<h2>ğŸ“Š å…³é”®è¯ç»Ÿè®¡</h2>
<table class="keywords-table">
<thead>
<tr>
<th>å…³é”®è¯</th>
<th>å‡ºç°æ¬¡æ•°</th>
</tr>
</thead>
<tbody>
<tr>
<td>single-cell</td>
<td>7</td>
</tr>
<tr>
<td>sequencing</td>
<td>6</td>
</tr>
<tr>
<td>regex:immuno(logy</td>
<td>therapy</td>
</tr>
<tr>
<td>methylation</td>
<td>5</td>
</tr>
<tr>
<td>tumor</td>
<td>5</td>
</tr>
<tr>
<td>RNA-seq</td>
<td>4</td>
</tr>
<tr>
<td>cardiac</td>
<td>4</td>
</tr>
<tr>
<td>cancer</td>
<td>4</td>
</tr>
<tr>
<td>transcriptomics</td>
<td>2</td>
</tr>
<tr>
<td>genome</td>
<td>2</td>
</tr>
<tr>
<td>aging</td>
<td>2</td>
</tr>
<tr>
<td>epigenetic</td>
<td>2</td>
</tr>
<tr>
<td>transcriptome</td>
<td>2</td>
</tr>
<tr>
<td>inflammation</td>
<td>2</td>
</tr>
<tr>
<td>carcinoma</td>
<td>1</td>
</tr>
<tr>
<td>scRNA</td>
<td>1</td>
</tr>
<tr>
<td>spatial</td>
<td>1</td>
</tr>
<tr>
<td>spatial transcriptomics</td>
<td>1</td>
</tr>
<tr>
<td>macrophage</td>
<td>1</td>
</tr>
<tr>
<td>pathway</td>
<td>1</td>
</tr>
</tbody>
</table>
<hr />
<h2>ğŸ“ æ›´å¤šå†…å®¹</h2>
<details>
<summary><a name="æ›´å¤š-æ•°æ®å‰æ²¿"></a>ğŸ§¬ æ•°æ®å‰æ²¿ å…¶ä»–å†…å®¹ (28æ¡)</summary>
<div class="details-content">
<ul>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE299798" target="_blank" rel="noopener noreferrer">GSE299798 ESR1 çš„æ¿€æ´»çªå˜å¯¼è‡´å…ç–«æŠ‘åˆ¶æ€§ä¹³è…ºè‚¿ç˜¤å¾®ç¯å¢ƒçš„å½¢æˆã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE294907" target="_blank" rel="noopener noreferrer">GSE294907 ç»´æŠ¤åŸºå› ç»„å®Œæ•´æ€§ï¼šPoloæ ·æ¿€é…¶Cdc5å’Œç£·é…¸é…¶Cdc14åè°ƒæ‹“æ‰‘å¼‚æ„é…¶IIä»‹å¯¼çš„æœ‰ä¸åˆ†è£‚é“¾ç¯è§£ç¦»</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE314368" target="_blank" rel="noopener noreferrer">GSE314368 ç»“ç›´è‚ ç™Œè¯±å‘æ¶ç—…è´¨å‘ç”Ÿå’Œå‘å±•è¿‡ç¨‹ä¸­éª¨éª¼è‚Œç”²åŸºåŒ–ç»„-è½¬å½•ç»„çš„ç´Šä¹±</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE303450" target="_blank" rel="noopener noreferrer">GSE303450 äººç±»å”¾æ¶²è…ºå’Œç±»å™¨å®˜çš„å•ç»†èƒRNAæµ‹åº</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE314110" target="_blank" rel="noopener noreferrer">GSE314110 é€šè¿‡AAV2/8ä»‹å¯¼é€’é€äººç±»ç™¾å²è€äººç›¸å…³SIRT6 N308K/A313Sï¼Œè°ƒæ§è‚ç»†èƒç™Œç»†èƒçš„ä¾µè¢­æ€§è½¬å½•</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE314066" target="_blank" rel="noopener noreferrer">GSE314066 è¿åŠ¨å¹²é¢„å‰åäººç±»ç²ªä¾¿å¾®ç”Ÿç‰©ç¾¤çš„16S rRNAåŸºå› æµ‹åº</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE301845" target="_blank" rel="noopener noreferrer">GSE301845 è…±ç”Ÿè›‹ç™½C+è‚Œæˆçº¤ç»´ç»†èƒé€šè¿‡ä¿ƒè¿›ç¥ç»-å·¨å™¬ç»†èƒç›¸äº’ä½œç”¨åŠ å‰§è¡€ç®¡å†…è†œå¢ç”Ÿ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE285475" target="_blank" rel="noopener noreferrer">GSE285475 å†…çš®è½¬å½•å› å­ EB å¯æŠµæŠ—é˜¿éœ‰ç´ è¯±å¯¼çš„å†…çš®æ¯’æ€§å’Œå¿ƒè„åŠŸèƒ½éšœç¢</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE262611" target="_blank" rel="noopener noreferrer">GSE262611ï¼šç”¨PI3K/AKT/mTORé€šè·¯æŠ‘åˆ¶å‰‚å¤„ç†çš„MPFRç»†èƒçš„å¾®é˜µåˆ—åŸºå› è¡¨è¾¾æ•°æ®ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE237200" target="_blank" rel="noopener noreferrer">GSE237200 å†…çš®è½¬å½•å› å­ EB å¯æŠµæŠ—é˜¿éœ‰ç´ è¯±å¯¼çš„å†…çš®æ¯’æ€§å’Œå¿ƒè„åŠŸèƒ½éšœç¢</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE287235" target="_blank" rel="noopener noreferrer">GSE287235 E8.75 é‡ç”Ÿå‹å’Œ Nr6a1 åŸºå› æ•²é™¤å°é¼ èƒšèƒçš„å¤šç»„å­¦ ATAC + åŸºå› è¡¨è¾¾æµ‹åº</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE287129" target="_blank" rel="noopener noreferrer">GSE287129 ä¸åŒçš„æŸ“è‰²è´¨è°ƒèŠ‚å› å­ä¸‹è°ƒå‡æ•°åˆ†è£‚è½´è›‹ç™½æ²‰ç§¯å’ŒæŸ“è‰²ä½“æœ«ç«¯çš„ DNA æ–­è£‚è¯±å¯¼ [ChIP-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE287127" target="_blank" rel="noopener noreferrer">GSE287127 ä¸åŒçš„æŸ“è‰²è´¨è°ƒèŠ‚å› å­ä¸‹è°ƒå‡æ•°åˆ†è£‚è½´è›‹ç™½æ²‰ç§¯å’ŒæŸ“è‰²ä½“æœ«ç«¯çš„ DNA æ–­è£‚è¯±å¯¼ [RNA-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE230046" target="_blank" rel="noopener noreferrer">GSE230046 äººç±»å¤šèƒ½å¹²ç»†èƒæ¥æºçš„èƒè‚ç±»å™¨å®˜ä¸­è‚é€ è¡€è°±ç³»çš„è½¬å½•ç»„</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE314256" target="_blank" rel="noopener noreferrer">GSE314256 è¿ç»­ä½å¼ºåº¦è¶…å£°é€šè¿‡ä¸‹è°ƒç‚ç—‡å’Œä¿ƒè¿› M2 æ ·æ ‡å¿—ç‰©æ¥å½±å“ M1 å·¨å™¬ç»†èƒçš„è½¬å½•ç»„è°±</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296724" target="_blank" rel="noopener noreferrer">GSE296724 RNA-seq åˆ†æé‡ç”Ÿå‹å’Œ Oxsr1 æ•²é™¤ HEK293T ç»†èƒçš„åŸºå› è¡¨è¾¾è°±</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE278465" target="_blank" rel="noopener noreferrer">GSE278465 NFÎºB1ç¼ºé™·ä¸Flt3é«“ç³»ç™½è¡€ç—…ç›¸å…³ï¼Œå¹¶é€šè¿‡RelA:p52å’ŒSOD2è¡¨è¾¾å¤±è°ƒå¢å¼ºç»†èƒè‡ªæˆ‘æ›´æ–°èƒ½åŠ›</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE314114" target="_blank" rel="noopener noreferrer">GSE314114 è°ƒæ§æ€§DNA:è›‹ç™½è´¨ç›¸äº’ä½œç”¨çš„å•ç»†èƒå®šä½ IV</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313521" target="_blank" rel="noopener noreferrer">GSE313521 å¤šæ¬¡å¿ƒè‚Œå†…æ³¨å°„è„å¸¦è¡€å•æ ¸ç»†èƒï¼ˆUCB-MNCsï¼‰åå¿ƒè„ä¿®å¤çš„ç‹¬ç‰¹è½¬å½•ç»„</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310767" target="_blank" rel="noopener noreferrer">GSE310767 ä½æ°´å¹³è¿·èµ°ç¥ç»åˆºæ¿€å¯¹å‹åŠ›è´Ÿè·è¿‡é‡è¯±å‘çš„å¿ƒåŠ›è¡°ç«­ä¸­å¿ƒè„é‡å¡‘å½±å“çš„è½¬å½•ç»„åˆ†æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE299431" target="_blank" rel="noopener noreferrer">GSE299431 è½¬å½•ç»„å­¦ç ”ç©¶ HeLa ç»†èƒä¸­ DNAJC15 å’Œ DNAJC19 çš„æ•²ä½</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296495" target="_blank" rel="noopener noreferrer">GSE296495 å•ç»†èƒè°ƒæ§DNA:è›‹ç™½è´¨ç›¸äº’ä½œç”¨å›¾è°±</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296493" target="_blank" rel="noopener noreferrer">GSE296493 å•ç»†èƒè°ƒæ§DNA:è›‹ç™½è´¨ç›¸äº’ä½œç”¨å›¾è°± III</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296492" target="_blank" rel="noopener noreferrer">GSE296492 å•ç»†èƒè°ƒæ§DNA:è›‹ç™½è´¨ç›¸äº’ä½œç”¨å›¾è°± II</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296491" target="_blank" rel="noopener noreferrer">GSE296491 è°ƒæ§æ€§DNA:è›‹ç™½è´¨ç›¸äº’ä½œç”¨çš„å•ç»†èƒå®šä½ I</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE287810" target="_blank" rel="noopener noreferrer">GSE287810 iPSCè¡ç”Ÿçš„è§’è´¨å½¢æˆç»†èƒç”¨äºç ”ç©¶ç‰¹åº”æ€§çš®ç‚çš„è¡¨çš®ç¼ºé™·[æ‰¹é‡RNAæµ‹åº]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE285002" target="_blank" rel="noopener noreferrer">GSE285002 ç–«è‹—é€’é€å¹³å°å½±å“åŸºäºè¡€å‡ç´ çš„æµæ„Ÿç–«è‹—åœ¨çŒªä½“å†…çš„å¼‚æºä¿æŠ¤ä½œç”¨</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE277703" target="_blank" rel="noopener noreferrer">GSE277703 LOXL2 è¯†åˆ«å‡ºä¸ç‚ç—‡ç›¸å…³çš„è‚Œæˆçº¤ç»´ç»†èƒï¼Œå¯é¢„æµ‹è‚¾ç§»æ¤åŠŸèƒ½éšœç¢å’Œçº¤ç»´åŒ–</a></li>
</ul>
</div>
</details>

<hr />
<p><em>ğŸ“… æŠ¥å‘Šç”Ÿæˆæ—¶é—´ï¼š2025-12-19 21:36</em><br />
<em>ğŸ¤– ç”± GitHub Actions è‡ªåŠ¨ç”Ÿæˆ</em></p>
    </div>
</body>
</html>